A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer

Molecular and Cellular Proteomics

Volumn 5, Issue 11, 2006, Pages 2083-2091

  Castronovo, Vincent ^a   Waltregny, David ^a   Kischel, Philippe ^a   Roesli, Christoph ^b   Elia, Giuliano ^b   Rybak, Jascha N ^b   Neri, Dario ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOCORTIN 4; MELANOMA ANTIGEN; MELANOMA ANTIGEN 50; TUMOR ANTIGEN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VERSICAN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BIOTINYLATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS;

ANTIGENS, NEOPLASM; BIOTINYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; PROTEOMICS; STREPTAVIDIN; TUMOR MARKERS, BIOLOGICAL;

EID: 33751416666     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.M600164-MCP200     Document Type: Article

References (48)

1. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., and Thorpe, P. E. (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275, 547-550
2. Wu, A. M., and Senter, P. D. (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-1146
3. Adams, G. P., and Weiner, L. M. (2005) Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-1157
4. Carter, P. (2001) Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118-129
5. Neri, D., and Bicknell, R. (2005) Tumour vascular targeting. Nat. Rev. Cancer 5, 436-446
6. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. (2000) Genes expressed in human tumor endothelium. Science 289, 1197-1202
7. Huminiecki, L., and Bicknell, R. (2000) In silico cloning of novel endothelial-specific genes. Genome Res. 10, 1796-1806
8. Pasqualini, R., and Ruoslahti, E. (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380, 364-366
9. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380
10. Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K. M., Carver, L. A., Testa, J. E., and Schnitzer, J. E. (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429, 629-635
11. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., and Aebersold, R. (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994-999
12. Saghatelian, A., and Cravatt, B. F. (2005) Assignment of protein function in the postgenomic era. Nat. Chem. Biol. 1, 130-142
13. Rybak, J. N., Ettorre, A., Kaissling, B., Giavazzi, R., Neri, D., and Elia, G. (2005) In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat. Methods 2, 291-298
14. Silacci, M., Brack, S., Schirru, G., Marlind, J., Ettorre, A., Merlo, A., Viti, F., and Neri, D. (2005) Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5, 2340-2350
15. Brack, S. S., Silacci, M., Birchler, M., and Neri, D. (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascln-C. Clin. Cancer Res. 12, 3200-3208
16. Takeshita, S., Kikuno, R., Tezuka, K., and Amann, E. (1993) Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem. J. 294, 271-278
17. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. (1994) Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455
18. Zardi, L., Camemolla, B., Siri, A., Petersen, T. E., Paolella, G., Sebastio, G., and Baralle, F. E. (1987) Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6, 2337-2342
19. Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., and Neri, D. (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273, 21769-21776
20. Castellani, P., Borsi, L., Carnemolla, B., Biro, A., Dorcaratto, A., Viale, G. L., Neri, D., and Zardi, L. (2002) Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol. 161, 1695-1700
21. Borsi, L., Balza, E., Bestagno, M., Castellani, P., Camemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., and Zardi, L. (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102, 75-85
22. Berndorff, D., Borkowski, S., Sieger, S., Rother, A., Friebe, M., Viti, F., Hilger, C. S., Cyr, J. E., and Dinkelborg, L. M. (2005) Radioimmuno-therapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin. Cancer Res. 11, 7053s-7063s
23. Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Bemdt, A., Ferrini, S., Kosmehl, H., Neri, D., and Zardi, L. (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99, 1659-1665
24. Ebbinghaus, C., Ronca, R., Kaspar, M., Grabulovski, D., Bemdt, A., Kosmehl, H., Zardi, L., and Neri, D. (2005) Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer 116, 304-313
25. Menrad, A., and Menssen, H. D. (2005) ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin. Ther. Targets 9, 491-500
26. Anderson, N. L., and Anderson, N. G. (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867
27. Sasaki, H., Yu, C. Y., Dai, M., Tam, C., Loda, M., Auclair, D., Chen, L. B., and Elias, A. (2003) Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res. Treat. 77, 245-252
28. Dorai, T., Sawczuk, I. S., Pastorek, J., Wiernik, P. H., and Dutcher, J. P. (2005) The role of carbonic anhydrase IX overexpression in kidney cancer. Eur. J. Cancer 41, 2935-2947
29. Mitchell, M. S., Kan-Mitchell, J., Minev, B., Edman, C., and Deans, R. J. (2000) A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T lymphocytes. Cancer Res. 60, 6448-6456
30. de Wit, N. J., Weidle, U. H., Ruiter, D. J., and van Muijen, G. N. (2002) Expression profiling of MMA-1a and splice variant MMA-1 b: new cancer/testis antigens identified in human melanoma. Int. J. Cancer 98, 547-553
31. Fabbri, M., Castellani, P., Gotwals, P. J., Kotelianski, V., Zardi, L., and Zocchi, M. R. (1996) A functional monoclonal antibody recognizing the human α1-integrin I-domain. Tissue Antigens 48, 47-51
32. Senger, D. R., Perruzzi, C. A., Streit, M., Koteliansky, V. E., de Fougerolles, A. R., and Detmar, M. (2002) The α(1)β(1) and α(2)β(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am. J. Pathol. 160, 195-204
33. Yano, Y., Hayashi, Y., Sano, K., Nagano, H., Nakaji, M., Seo, Y., Ninomiya, T., Yoon, S., Yokozaki, H., and Kasuga, M. (2004) Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E-NPP3/CD203c/PD-1β/B10/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases. Cancer Lett. 207, 139-147
34. Uhlen, M., Bjorling, E., Agaton, C., Szigyarto, C. A., Amini, B., Andersen, E., Andersson, A. C., Angelidou, P., Asplund, A., Asplund, C., et al. (2005) A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics 4, 1920-1932
35. Ismail, R. S., Baldwin, R. L., Fang, J., Browning, D., Karlan, B. Y., Gasson, J. C., and Chang, D. D. (2000) Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 60, 6744-6749
36. Shao, R., Bao, S., Bai, X., Blanchette, C., Anderson, R. M., Dang, T., Gishizky, M. L., Marks, J. R., and Wang, X. F. (2004) Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol. Cell. Biol. 24, 3992-4003
37. Sasaki, H., Lo, K. M., Chen, L. B., Auclair, D., Nakashima, Y., Moriyama, S., Fukai, I., Tam, C., Loda, M., and Fujii, Y. (2001) Expression of Periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn. J. Cancer Res. 92, 869-873
38. Tai, I. T., Dai, M., and Chen, L. B. (2005) Periostin induction in tumor cell line explants and inhibition of in vitro cell growth by anti-periostin antibodies. Carcinogenesis 26, 908-915
39. Pukkila, M. J., Kosunen, A. S., Virtaniemi, J. A., Kumpulainen, E. J., Johansson, R. T., Kellokoski, J. K., Nuutinen, J., and Kosma, V. M. (2004) Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study. J. Clin. Pathol. 57, 735-739
40. Voutilainen, K., Anttila, M., Sillanpaa, S., Tammi, R., Tammi, M., Saarikoski, S., and Kosma, V. M. (2003) Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int. J. Cancer 107, 359-364
41. Suwiwat, S., Ricciardelli, C., Tammi, R., Tammi, M., Auvinen, P., Kosma, V. M., LeBaron, R. G., Raymond, W. A., Tilley, W. D., and Horsfall, D. J. (2004) Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin. Cancer Res. 10, 2491-2498
42. Pirinen, R., Leinonen, T., Bohm, J., Johansson, R., Ropponen, K., Kumpulainen, E., and Kosma, V. M. (2005) Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum. Pathol 36, 44-50
43. Mauri, P., Scarpa, A., Nascimbeni, A. C., Benazzi, L., Parmagnani, E., Mafficini, A., Delia Peruta, M., Bassi, C., Miyazaki, K., and Sorio, C. (2005) Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J. 19, 1125-1127
44. Lambert, J. M. (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol, 5, 543-549
45. Kaspar, M., Zardi, L., and Neri, D. (2006) Fibronectin as target for tumor therapy. Int. J Cancer 118, 1331-1339
46. Silacci, M., Brack, S. S., Spaeth, N., Buck, A., Hillinger, S., Arni, S., Weder, W., Zardi, L., and Neri, D. (2006) Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng. Des. Sel., in press
47. Christian, S., Pilch, J., Akerman, M. E., Porkka, K., Laakkonen, P., and Ruoslahti, E. (2003) Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 163, 871-878
48. Warford, A., Howat, W., and McCafferty, J. (2004) Expression profiling by high-throughput immunohistochemistry. J. Immunol. Methods 290, 81-92